Dr Nader Omidvar
Research Associate
Publication
2025
2024
2021
2020
2017
2016
2015
- Pogam, C. L. et al. 2015. DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. Oncotarget 6(32), pp. 32494-32508. (10.18632/oncotarget.5572)
- Piggott, L., Omidvar, N., Martí Pérez, S., French, R., Eberl, M. and Clarkson, R. W. E. 2015. Erratum to: Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Research 17(1), pp. 96. (10.1186/s13058-015-0597-9)
2013
2011
- Piggott, L., Omidvar, N., Marti-Perez, S., Eberl, M. and Clarkson, R. W. E. 2011. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Research 13(5), article number: R88. (10.1186/bcr2945)
- Kreuzaler, P. A. et al. 2011. Stat3 controls lysosomal-mediated cell death in vivo. Nature Cell Biology 13(3), pp. 303-309. (10.1038/ncb2171)
2008
- Tiffen, P., Omidvar, N., Marquez, N., Croston, D., Watson, C. and Clarkson, R. W. E. 2008. A dual role for Oncostatin M signalling in the differentiation and death of mammary epithelial cells in vivo. Molecular Endocrinology 22(12), pp. 2677-2688. (10.1210/me.2008-0097)
2007
2006
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. The Journal of Immunology 176(5), pp. 2915-2923. (10.4049/jimmunol.176.5.2915)
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176(5), pp. 2915-2923.
- Omidvar, N., Pearn, L., Burnett, A. K. and Darley, R. L. 2006. Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras. Molecular and cellular biology 26(10), pp. 3966-75. (10.1128/MCB.26.10.3966-3975.2006)
2005
2004
- Baalasubramanian, S., Harris, C. L., Donev, R. M., Mizuno, M., Omidvar, N., Song, W. and Morgan, B. P. 2004. CD59a is the primary regulator of membrane attack complex assembly in the mouse. Journal of Immunology 173, pp. 3684-3692.
- Sivasankar, B., Mizuno, M., Donev, R. M., Omidvar, N., Harris, C. L., Song, W. C. and Morgan, B. P. 2004. CD59b is expressed at low level on mouse erythrocytes and has a negligible protective role in the presence of CD59a. Molecular Immunology 41(2-3), pp. 307-308. (10.1016/j.molimm.2004.03.002)
2002
Articles
- Dolton, G. et al. 2025. MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.. The Journal of Clinical Investigation 135(1), article number: e181895. (10.1172/JCI181895)
- Dolton, G. et al. 2024. HLA A*24:02-restricted T-cell receptors cross recognise bacterial and preproinsulin peptides in type 1 diabetes. Journal of Clinical Investigation 134(18), article number: e164535. (10.1172/JCI164535)
- Hajeyah, A. A. et al. 2024. Phosphatidylthreonine is a procoagulant lipid detected in human blood and elevated in coronary artery disease.. Journal of Lipid Research 65(1), article number: 100484. (10.1016/j.jlr.2023.100484)
- Gorombei, P. et al. 2021. BCL-2 Inhibitor ABT-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a NRAS/BCL-2 mouse model of high risk-myelodysplastic syndrome. International Journal of Molecular Sciences 22(19), article number: 10658. (10.3390/ijms221910658)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)
- Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80(5), pp. 937-949. (10.1158/0008-5472.CAN-19-1920)
- Carr, R. et al. 2017. The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions. Leukemia and Lymphoma 58(5), pp. 1178-1183. (10.1080/10428194.2016.1231308)
- Tekin, N. et al. 2016. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: validation of the six-gene predictor score. Oncotarget 7(50), pp. 83319-83329. (10.18632/oncotarget.13066)
- Keeshan, K. et al. 2016. Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBP as a common target of TRIB1 and PML/RARA. Haematologica 101(10), pp. 1228-1036. (10.3324/haematol.2015.138503)
- Guerenne, L. et al. 2016. GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. Journal of Hematology & Oncology 9(5), article number: PMC4728810. (10.1186/s13045-016-0235-8)
- Pogam, C. L. et al. 2015. DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies. Oncotarget 6(32), pp. 32494-32508. (10.18632/oncotarget.5572)
- Piggott, L., Omidvar, N., Martí Pérez, S., French, R., Eberl, M. and Clarkson, R. W. E. 2015. Erratum to: Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Research 17(1), pp. 96. (10.1186/s13058-015-0597-9)
- Le Pogam, C. et al. 2013. Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. Leukemia Research 37(3), pp. 312-319. (10.1016/j.leukres.2012.10.018)
- Omidvar, N. et al. 2013. PML-RAR co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica 98(3), pp. 424-427. (10.3324/haematol.2011.057067)
- Piggott, L., Omidvar, N., Marti-Perez, S., Eberl, M. and Clarkson, R. W. E. 2011. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Research 13(5), article number: R88. (10.1186/bcr2945)
- Kreuzaler, P. A. et al. 2011. Stat3 controls lysosomal-mediated cell death in vivo. Nature Cell Biology 13(3), pp. 303-309. (10.1038/ncb2171)
- Tiffen, P., Omidvar, N., Marquez, N., Croston, D., Watson, C. and Clarkson, R. W. E. 2008. A dual role for Oncostatin M signalling in the differentiation and death of mammary epithelial cells in vivo. Molecular Endocrinology 22(12), pp. 2677-2688. (10.1210/me.2008-0097)
- Rassool, F. V. et al. 2007. Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia?. Cancer Research 67(18), pp. 8762-8771. (10.1158/0008-5472.CAN-06-4807)
- Omidvar, N. et al. 2007. BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia. Cancer Research 67(24), pp. 11657-11667. (10.1158/0008-5472.CAN-07-0196)
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. The Journal of Immunology 176(5), pp. 2915-2923. (10.4049/jimmunol.176.5.2915)
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176(5), pp. 2915-2923.
- Omidvar, N., Pearn, L., Burnett, A. K. and Darley, R. L. 2006. Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras. Molecular and cellular biology 26(10), pp. 3966-75. (10.1128/MCB.26.10.3966-3975.2006)
- Longhi, M. P., Baalasubramanian, S., Omidvar, N., Morgan, B. P. and Gallimore, A. M. 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175(11), pp. 7098-7102.
- Baalasubramanian, S., Harris, C. L., Donev, R. M., Mizuno, M., Omidvar, N., Song, W. and Morgan, B. P. 2004. CD59a is the primary regulator of membrane attack complex assembly in the mouse. Journal of Immunology 173, pp. 3684-3692.
- Sivasankar, B., Mizuno, M., Donev, R. M., Omidvar, N., Harris, C. L., Song, W. C. and Morgan, B. P. 2004. CD59b is expressed at low level on mouse erythrocytes and has a negligible protective role in the presence of CD59a. Molecular Immunology 41(2-3), pp. 307-308. (10.1016/j.molimm.2004.03.002)
- Darley, R. L. et al. 2002. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 100(12), pp. 4185-92. (10.1182/blood-2002-05-1358)